Adipocytokine Imbalance and Ghrelin in the Development of Insulin Resistance in Patients with Chronic Hepatitis C

Larisa Tkachenko, PhD*¹; Viktor Maleev, PhD, ScD²; Ludmila Rtishcheva, PhD, ScD¹

¹Stavropol State Medical University, Stavropol, Russia; ²Central Research Institute of Epidemiology, the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russia

 *Corresponding authorLarisa Tkachenko, PhD. The Stavropol State Medical University, Russia. E-mail:

Published: March 16, 2016. DOI: 10.21103/Article6(1)_OA5


The aim of this study was to determine the role of the most informative indicators of adipocytokine status and ghrelin in insulin resistance (IR) formation in chronic hepatitis C (CHC) patients at different stages of liver fibrosis (LF).

Materials and Methods: This study included 205 CHC patients with HCV genotypes 1 and 3. A comparative analysis of the laboratory parameters was carried out in a group of patients with IR (n=110) and without IR (n=95) and in patients depending on the stage of LF. The serum levels of adipocytokines and ghrelin were determined using Bachem Group (USA) and Immundiagnostik AG (Germany) test systems with microplate reader Elx800 (FinBio, Finland). Diagnosis and assessment of the degree of fibrosis was performed by liver biopsy, liver elastometry and calculation test FibroTest.

Results: Obtained data allow us to regard the decreased secretion of ghrelin, and increased production of leptin, resistin and TNF-α as a component involved in the formation of IR in CHC patients.

chronic hepatitis C; adipocytokines; ghrelin; insulin resistance.
  1. Mohd Hanafi ah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology, 2013, 57(4):1333–42.
  2. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29:74–81.
  3. Galossi A, Guarisco R, Bellis L, Puoti C. Extrahepatic Manifestations of Chronic HCV Infection. J Gastrointestin Liver Dis March. 2007;16:65–73.
  4. El-Zayadi AR1, Anis M  Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol. 2012;18(3):212-24. doi: 10.3748/wjg.v18.i3.212.
  5. Machado MV, Cortez-Pinto H. Insulin resistance and steatosis in chronic hepatitis C. A. nn Hepatol. 2009;8:S67–S75.
  6. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C--natural history and cofactors. Aliment Pharmacol Ther. 2005;22(Suppl 2):74–78
  7. Ioannou GN, Ioannou GN, Bryson CL, Boyko EJ. Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes. J Diabetes Complications. 2007; 21:363–370
  8. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Järvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR) Hypertension. 1997;30:1144–1149
  9. Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol.2006;12:7075–80.
  10. Harrison SA. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol. 2008;6:864–76. 
  11. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:416–423
  12. Jalil S, Mummad RR, Sood GK Chronic HCV infection causes insulin resistance—a meta-analysis (abstr).Gastroenterology. 2007; 132:(Suppl 2):A-784.
  13. Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World J Gastroenterol. 2010; 16: 1943-52.  
  14. Leclercq IA, Morais AS, Schroyen B, Hul NV, Geerts  A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. 2007; 47:142–56.
  15. Mori K, Yoshimoto A, Takaya K, Hosoda K, Ariyasu H, Yahata K, et al. Kidney produces a novel acylated peptide, ghrelin. FEBS Lett. 2000; 486: 213–6.
  16. Marra F, Bertolani C. Adipokines in Liver Diseases. Hepatology. 2009; 50 (3): 957- 69.
  17. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection European Association for the Study of the Liver. J Hepatology. 2014; 60(2):392–420.
  18. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-62.
  19. Hui J M, Sud A, Farrell GC, Bandara P, Byth K,. Kench J G, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression Gastroenterology. 2003;125:1695–1704.
  20. Zein CO, Levy C, Basu A, Zein NN .Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005;100:48–55
  21. Knobler H1, Schattner A.TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. QJM. 2005 Jan;98(1):1-6.
  22. Knobler H1, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol. 2003; 98(12):2751-6.
  23. Greenberg AS1, McDaniel ML.Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes.Eur J Clin Invest. 2002 Jun;32 Suppl 3:24-34.
  24. Sanyal AJ,  Contos MJ,  Sterling RK, Luketic  VA, Shiffman M L,  Stravitz RT et al. Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: a potential mechanisms for failure of interferon therapy in subjects with HCV and nonalcoholic fatty liver disease. Hepatology. 2004; 40:179A
  25. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, UtiliR, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
  26. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ: Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey (NHANES III).Diabetes Res Clin Pract. 2007; 75:320–6.
  27. Reaven G.M. Compensatory hyperinsulinemia and the development of the atherogenic lipoprotein profile. The price paid to maintain glucose homeostasis in insulin-resistant individuals Endocrinol Metab Clin North Am. 2005; 34: 49-62
  28. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586–597
  29. McGuinness PH, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut. 2000;46:260–269.
  30. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–379
  31. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases Am. J. Gastroenterol. 2006; 101 (11): 2629-2640
  32. Mattioli B, Straface E, Quaranta MG, Giordani L, Viora M. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming. J Immunol 2005; 174:6820-6828
  33. Dixit VD, Schaffer EM, Pуle RS , Collins G D, Sakthivel SK, Palaniappan R, et al. Ghrelin inhibits leptin and activation-induced proinflammatory cytokine expression by human monocytes and T-cells J Clin Inv 2004; 114: 57-66.
  34. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection  Mayo. Clin. Proc. 2000; 75: 355-59.
  35. Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury Diabetes Care 2004; 27: 1171-75.
  36. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, Brun JM, Hillon P: Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001; 35: 279 –83.
  37. Cammà C1, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. 2006;43(1):64-71.
  38. Castéra L1, Hézode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003;52(2):288-92.
  39. Tazawa J, Maeda M, Nakagawa M, Ohbayashi H, Kusano F, Yamane M, et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci. 2002; 47:710 –15.
  40. Lecube A1, Hernández C, Genescà J, Simó R.Glucose abnormalities in patients with hepatitis C virus infection: Epidemiology and pathogenesis.Diabetes Care. 2006 May;29(5):1140-9
  41. Paradis V1, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al.High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis.Hepatology. 2001;34(4 Pt 1):738-44.
  42. Schäffler A1, Schölmerich J, Büchler C.Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005; 2(6):273-80.
  43. Baranova A1, Jarrar MH, Stepanova M, Johnson A, Rafiq N, Gramlich T, Chandhoke V, Younossi ZM. Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C.Digestion. 2011;83(1-2):32-40.

The fully formatted PDF version is available.

Download Article

Int J Biomed. 2016; 6(1):27-32. © 2016 International Medical Research and Development Corporation. All rights reserved.